Immunotherapy combo shows promise in stopping melanoma recurrence after surgery
NCT ID NCT04013854
First seen Nov 06, 2025 · Last updated May 08, 2026 · Updated 21 times
Summary
This study tests whether giving immunotherapy drugs (nivolumab alone or with ipilimumab) after melanoma surgery can prevent the cancer from coming back. 67 adults with stage III melanoma that can be removed by surgery will receive one dose of nivolumab before surgery, then continue treatment for up to a year based on how their tumor responded. The goal is to see if this approach improves recurrence-free survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center, University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Duke Cancer Institute
Durham, North Carolina, 27710, United States
-
Lancaster General Hospital
Lancaster, Pennsylvania, 17601, United States
Conditions
Explore the condition pages connected to this study.